Mela Sciences ($MELA), a New York melanoma diagnostic device company, has raised $27.3 million in new financing to help it win reimbursement and pursue more clinical testing for its MelaFind system, which has U.S. and EU approval to help dermatologists diagnose melanoma. As our sister publication FierceMedicalDevices reported, Mela's shares dropped below the $1 minimum share price a few weeks ago. To maintain its listing, Mela did a one-for-10 reverse stock split, and the new investor financing followed. More